Studies have shown that amongst many factors, part of them are explained by age, sex, baseline DAS28 score, presence of rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibodies (ACPA), type of treatment given, anxiety, coping with pain and locus of control (the extent to which patients believe they can control the pain) (Xiong H, Kuijper TM, de Jong PHP, Weel AEAM, Gerards AH, van Zeben J, et al.: Higher levels of baseline anxiety is a predictor of disease activity at three months in early arthritis patients initiating therapy with DMARDs, submitted) [5–10]. The gene discussed is PRTN3; the disease is Anxiety.